Results 321 to 330 of about 179,002 (365)
Graft-Versus-Host Disease [PDF]
Annual Review of Medicine, 1991 Graft-versus-host disease, both acute and chronic, continues to be the major complication of human bone marrow transplantation. Improved posttransplant chemoprophylaxis has reduced the incidence of acute graft-versus-host disease, but the incidence of the chronic form of the disease remains unchanged.
James L.M. Ferrara, H. J. Deeg
+8 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 1997
Graft-versus-host disease (GVHD) continues to be a major obstacle to the success of allogeneic bone marrow transplantation. Furthermore, several clinical strategies being employed at this time in the field of bone marrow transplantation have had an impact on GVHD.
Georgia B. Vogelsang, Deborah Marcellus
openaire +5 more sources
Graft-versus-host disease (GVHD) continues to be a major obstacle to the success of allogeneic bone marrow transplantation. Furthermore, several clinical strategies being employed at this time in the field of bone marrow transplantation have had an impact on GVHD.
Georgia B. Vogelsang, Deborah Marcellus
openaire +5 more sources
Graft-versus-host disease [PDF]
Nature Reviews Immunology, 2007 Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alphabeta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient.
openaire +2 more sources
Current Opinion in Oncology, 1994
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors.
openaire +5 more sources
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors.
openaire +5 more sources
Chronic Graft-versus-Host Disease
Current Pharmaceutical Design, 2008Chronic graft-versus-host disease is the most common late, non-relapse complication of transplantation yet it is also one of the least studied. It is the primary cause of morbidity and mortality of long-term survivors of allogeneic bone marrow transplants. Like acute graft-versus-host disease, it does have a strong antitumor effect. The recent National
Georgia B. Vogelsang +1 more
openaire +3 more sources
2016
Graft-versus-host disease (GVHD) is arbitrarily divided into acute and chronic forms. The acute form of the disease ordinarily occurs between 21 and 60 days following bone marrow transplantation. Patients develop maculopapular or scarlatiniform eruptions.
Rachel L. Mistur +2 more
openaire +4 more sources
Graft-versus-host disease (GVHD) is arbitrarily divided into acute and chronic forms. The acute form of the disease ordinarily occurs between 21 and 60 days following bone marrow transplantation. Patients develop maculopapular or scarlatiniform eruptions.
Rachel L. Mistur +2 more
openaire +4 more sources
Ocular graft-versus-host disease
Current Opinion in Allergy & Clinical Immunology, 2012This review was carried out to study the frequency, and severity of ocular surface involvement at the setting of allogeneic hematopoietic stem cell transplantation and subsequent graft-versus-host disease (GVHD) and evaluate the clinical outcomes of newer treatments.Ocular involvement has been reported in 60-90% of patients with chronic GVHD.
Esen K. Akpek, Michelle Hessen
openaire +3 more sources